Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

2.14
+0.18009.18%
Post-market: 2.09-0.0499-2.33%18:37 EST
Volume:274.16K
Turnover:577.16K
Market Cap:129.63M
PE:-0.97
High:2.19
Open:2.00
Low:2.00
Close:1.96
52wk High:2.46
52wk Low:0.8551
Shares:60.57M
Float Shares:32.93M
Volume Ratio:2.30
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2064
EPS(LYR):-1.7051
ROE:-85.93%
ROA:-42.23%
PB:1.39
PE(LYR):-1.26

Loading ...

Company Profile

Company Name:
Acumen Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
61
Office Location:
1210-1220 Washington St.,Suite 210,Newton,Massachusetts,United States
Zip Code:
02465
Fax:
- -
Introduction:
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Directors

Name
Position
Daniel O'Connell
Chief Executive Officer and Director
George Golumbeski
Chairman of the Board and Director
Derrell Porter
Independent Director
Jeffrey L. Ives
Independent Director
Kimberlee C. Drapki
Independent Director
Laura Stoppel
Independent Director
Nathan B. Fountain
Independent Director

Shareholders

Name
Position
Daniel O'Connell
Chief Executive Officer and Director
Russell Barton
Chief Operating Officer
Matthew Zuga
Chief Financial Officer and Chief Business Officer
Amy Schacterle
Chief Regulatory Officer, Head of Quality
Derek Meisner
Chief Legal Officer
Eric Siemers
Chief Medical Officer
Jim Doherty
President and Chief Development Officer